Active Ingredient(s): Efgartigimod Alfa
FDA Approved: * December 17, 2021
Pharm Company: * ARGENX BV

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vyvgart Overview

Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis.[1][2] The most common side effects include respiratory tract infections, headache, and urinary tract infections.[2] Efgartigimod alfa is a neonatal Fc receptor blocker and is a new class of medication.[2] It is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (Ig...

Read more Vyvgart Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Efgartigimod_alfa

Recent Vyvgart Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Efgartigimod Alfa
  • Injection: 400mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Efgartigimod Alfa or a similar ingredient: (1 result)